News Results
There are 370,210 News Results
Aug 20, 2024
RYBREVANT(® )plus LAZCLUZE(TM) is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib
Sep 8, 2024
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT(®) plus LAZCLUZE(TM) regimen compared to osimertinib monotherapy as first-line therapy
Sep 10, 2024
Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT(®), a three-fold reduction from 67.4 percent historically seen with standard IRR management
Sep 14, 2024
Post-progression outcomes showed significant and sustained improvement for RYBREVANT(®) plus standard of care versus chemotherapy alone
Sep 19, 2024
Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT(®) this year, with four indications overall
Oct 16, 2024
Woodside Energy Group (ASX: WDS) (NYSE: WDS) (LSE: WDS): Woodside CEO Meg O’Neill said: “We would like to acknowledge the tragic death in early October of an employee of one...
Oct 17, 2024
Martin Midstream Partners L.P. (Nasdaq: MMLP) (“MMLP” or the “Partnership”) today announced its financial results for the third quarter of 2024. Bob Bondurant, President and Chief Executive Officer of Martin...
Oct 24, 2024
Expro Group Holdings N.V. (NYSE: XPRO) (the “Company” or “Expro”) today reported financial and operational results for the three and nine months ended September 30, 2024. Third Quarter 2024 Highlights...
Oct 24, 2024
-- New five-year data reinforce long-term safety and efficacy of SPRAVATO(®) (esketamine) in patients with inadequate response to two or more oral antidepressants (treatment-resistant depression) -- 23 abstracts highlight data...
